[1] Li Y, Yan L, Wang R, et al. Serum Immunoglobulin G Levels Predict Biochemical and Histological Remission of Autoimmune Hepatitis Type 1: A Single-Center Experience and Literature Review. Clin Rev Allergy Immunol,2022,62(2):292-300.
[2] Hu M, You Z, Li Y, et al. Serum Biomarkers for Autoimmune Hepatitis Type 1: the Case for CD48 and a Review of the Literature. Clin Rev Allergy Immunol,2022, 63(3):342-356.
[3] Pape S, Snijders RJALM, Gevers TJG, et al. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. J Hepatol,2022,76(4):841-849.
[4] Li Y, Xiao X, Miao Q, et al. Rapid response predicts complete biochemical response and histological remission in autoimmune hepatitis. J Hepatol,2022,77(5):1463-1464.
[5] Corpechot C, Carrat F, Gaouar F, et al. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. J Hepatol,2022,77(6):1545-1553.
[6] Vuppalanchi R, Caldwell SH, Pyrsopoulos N, et al. Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis. J Hepatol,2022,76(1):75-85.
[7] Bowlus CL, Galambos MR, Aspinall RJ, et al. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. J Hepatol, 2022,77(2):353-364.
[8] Villard C, Friis-Liby I, Rorsman F, et al. Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis. J Hepatol,2022:S0168-8278(22)03303-7.
[9] Trauner M, Bowlus CL, Gulamhusein A, et al. Safety and sustained efficacy of the farnesoid X receptor (FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC. Clin Gastroenterol Hepatol,2022:S1542-3565(22)00720-0.
[10] Kowdley KV, Forman L, Eksteen B, et al. A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholate in Patients With Primary Sclerosing Cholangitis. Am J Gastroenterol,2022,117(11):1805-1815.
[11] Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. Hepatology. 2022 Apr;75(4):1012-1013.
[12] Bowlus CL, Arrivé L, Bergquist A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology,2022:S1542-3565(22)01021-7.
[13] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol,2022,7(3):761-806.
[14] Li Y, Sun Y, Liu Y, et al. Genome-wide meta-analysis identifies susceptibility loci for autoimmune hepatitis type 1. Hepatology,2022,76(3):564-575.
[15] Huang B, Lyu Z, Qian Q, et al. NUDT1 promotes the accumulation and longevity of CD103(+) T(RM) cells in primary biliary cholangitis. J Hepatol,2022, 77(5):1311-1324.
[16] Liu Q, Li B, Li Y, et al. Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis. Gut,2022,71(5):899-909. |
